Download PDF
Dtsch Med Wochenschr 2003; 128(30): 1602-1608
DOI: 10.1055/s-2003-40934
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Neuere Erkenntnisse zur Pathogenese der Steroidosteoporose

Auswirkungen für Therapie und PräventionNew data on the pathogenesis of steroid-induced osteoporosisConsequences for therapy and preventionM. Hüfner1 , H. Siggelkow1
  • 1Institut:Schwerpunkt Endokrinologie, Abteilung Gastroenterologie und Endokrinologie, Medizinische Universitätsklinik, Göttingen
Further Information

Publication History

eingereicht: 17.12.2002

akzeptiert: 10.7.2003

Publication Date:
28 July 2003 (online)

Also available at
    Permissions and Reprints

Das Auftreten einer Osteoporose bei endogenem Hyperkortizismus wurde schon von Cushing beschrieben. Nach Einführung der Glukokortikoide in die Pharmakotherapie wurde sehr schnell offensichtlich, dass die Osteoporose eine der schwerwiegendsten Nebenwirkungen dieser Therapie ist. Die Glukokortikoid-induzierte-Osteoporose (GIOP) ist die dritthäufigste Osteoporoseform nach der postmenopausalen Osteoporose und der Altersosteoporose.

Wegen der multiplen zellulären Wirkorte der Glukokortikoide auf den Knochen ist die Pathophysiologie der Steroidosteoporose sehr komplex, und die experimentellen Befunde sind zum Teil kontrovers. Erhebliche Fortschritte im Verständnis des Knochenstoffwechsels werfen ein neues Licht auf die Wirkung von Glukokortikoiden am Knochen. In dieser Übersicht werden aktuell epidemiologische und experimentelle Untersuchungsergebnisse dargestellt, um daraus eine pathophysiologisch begründete Therapie herzuleiten. Schließlich soll auf mögliche neue therapeutische Entwicklungen in der Zukunft hingewiesen werden.

Literatur

  • 1 Adachi J D, Bensen W G, Brown J, Hanley D, Hodsman A, Josse R, Kendler D L, Lentle B, Olszynski W, Ste-Marie L G, Tenenhouse A, Chines A A. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.  N Engl J Med. 1997;  337 382-387
    Google Scholar
  • 2 Adachi J D, Roux C, Pitt P I, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley M I, Jenkins E A, Walker-Bone K E, Pack S, Stephenson G F, Laan R F, Brown J, Geusens P. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.  J Rheumatol. 2000;  27 2424-2431
    Google Scholar
  • 3 Adachi J D, Saag K G, Delmas P D, Liberman U A, Emkey R D, Seeman E, Lane N E, Kaufman J M, Poubelle P E, Hawkins F, Correa-Rotter R, Menkes C J, Rodriguez-Portales J A, Schnitzer T J, Block J A, Wing J, McIlwain H H, Westhovens R, Brown J, Melo-Gomes J A, Gruber B L, Yanover M J, Leite M O, Siminoski K G, Nevitt M C, Sharp J T, Malice M P, Dumortier T, Czachur M, Carofano W, Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.  Arthritis Rheum. 2001;  44 202-211
    Google Scholar
  • 4 Bamberger C M, Schulte H M. Molecular mechanisms of dissociative glucocorticoid activity.  Eur J Clin Invest. 2000;  30 6-9 (Suppl 3)
    Google Scholar
  • 5 Canalis E, Delany A M. Mechanisms of glucocorticoid action in bone.  Ann N Y Acad Sci. 2002;  966 73-81
    Google Scholar
  • 6 Chapuy M C, Arlot M E, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas P D, Meunier P J. Vitamin D3 and calcium to prevent hip fractures in the elderly women.  N Engl J Med. 1992;  327 1637-1642
    Google Scholar
  • 7 Chapuy M C, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier P J. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.  Osteoporos Int. 2002;  13 257-264
    Google Scholar
  • 8 Crandall C. Parathyroid hormone for treatment of osteoporosis.  Arch Intern Med. 2002;  162 2297-2309
    Google Scholar
  • 9 Hofbauer L C, Gori F, Riggs B L, Lacey D L, Dunstan C R, Spelsberg T C, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.  Endocrinology. 1999;  140 4382-4389
    Google Scholar
  • 10 Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Boyle W J, Riggs B L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.  J Bone Miner Res. 2000;  15 2-12
    Google Scholar
  • 11 Jilka R L, Weinstein R S, Bellido T, Roberson P, Parfitt A M, Manolagas S C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.  J Clin Invest. 1999;  104 439-446
    Google Scholar
  • 12 Jones A, Fay J K, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease.  Cochrane Database Syst Rev. 2002;  CD003537
    Google Scholar
  • 13 Lane N E, Sanchez S, Modin G W, Genant H K, Pierini E, Arnaud C D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.  J Clin Invest. 1998;  102 1627-1633
    Google Scholar
  • 14 Leischker H, Kolb G F. Therapeutical use of parathyroid hormone.  Dtsch Med Wochenschr. 2002;  127 624-626
    Google Scholar
  • 15 Luckman S P, Hughes D E, Coxon F P, Graham R, Russell G, Rogers M J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.  J Bone Miner Res. 1998;  13 581-589
    Google Scholar
  • 16 Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat J M, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.  Thorax. 1991;  46 803-806
    Google Scholar
  • 17 Nutall M E, Patton A J, Olivera D L, Nadeau D P, Gowen M. Human trabecular bone cells are able to express both osteoblasic and adipocytic phenotype: implications for osteopenic disorders.  J Bone Miner Res. 1998;  13 371-382
    Google Scholar
  • 18 Nuttall M E, Gimble J M. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?.  Bone. 2000;  27 177-184
    Google Scholar
  • 19 Okada N, Nomura M, Morimoto S, Ogihara T, Yoshikawa K. Bone mineral density of the lumbar spine in psoriatic patients with long term etretinate therapy.  J Dermatol. 1994;  21 308-311
    Google Scholar
  • 20 Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis.  Bone. 2001;  29 498-505
    Google Scholar
  • 21 Peacey S R, Guo C Y, Robinson A M, Price A, Giles M A, Eastell R, Weetman A P. Glucocorticoid replacement therapy: are patients over treated and does it matter?.  Clin Endocrinol (Oxf). 1997;  46 255-261
    Google Scholar
  • 22 Pearce G, Tabensky D A, Delmas P D, Baker H W, Seeman E. Corticosteroid-induced bone loss in men.  J Clin Endocrinol Metab. 1998;  83 801-806
    Google Scholar
  • 23 Pereira R C, Delany A M, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression.  Bone. 2002;  30 685-691
    Google Scholar
  • 24 Plotkin L I, Weinstein R S, Parfitt A M, Roberson P K, Manolagas S C, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.  J Clin Invest. 1999;  104 1363-1374
    Google Scholar
  • 25 Reid D M, Hughes R A, Laan R F, Sacco-Gibson N A, Wenderoth D H, Adami S, Eusebio R A, Devogelaer J P. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.  J Bone Miner Res. 2000;  15 1006-1013
    Google Scholar
  • 26 Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, Kotchen J M, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.  Jama. 2002;  288 321-333
    Google Scholar
  • 27 Rubin M R, Bilezikian J P. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence.  J Clin Endocrinol Metab. 2002;  87 4033-4041
    Google Scholar
  • 28 Saag K G, Emkey R, Schnitzer T J, Brown J P, Hawkins F, Goemaere S, Thamsborg G, Liberman U A, Delmas P D, Malice M P, Czachur M, Daifotis A G. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.  N Engl J Med. 1998;  339 292-299
    Google Scholar
  • 29 Tauchmanova L, Rossi R, Nuzzo V, del Puente A, Esposito-del Puente A, Pizzi C, Fonderico F, Lupoli G, Lombardi G. Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass.  Eur J Endocrinol. 2001;  145 241-247
    Google Scholar
  • 30 Van Staa T P, Leufkens H G, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures.  J Bone Miner Res. 2000;  15 993-1000
    Google Scholar
  • 31 Vayssiere B M, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.  Mol Endocrinol. 1997;  11 1245-1255
    Google Scholar
  • 32 Viereck V, Emons G, Lauck V, Frosch K H, Blaschke S, Grundker C, Hofbauer L C. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.  Biochem Biophys Res Commun. 2002;  291 680-686
    Google Scholar
  • 33 Wallach S, Cohen S, Reid D M, Hughes R A, Hosking D J, Laan R F, Doherty S M, Maricic M, Rosen C, Brown J, Barton I, Chines A A. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.  Calcif Tissue Int. 2000;  67 277-285
    Google Scholar
  • 34 Weinstein R S, Chen J R, Powers C C, Stewart S A, Landes R D, Bellido T, Jilka R L, Parfitt A M, Manolagas S C. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.  J Clin Invest. 2002;  109 1041-1048
    Google Scholar
  • 35 Weinstein R S, Jilka R L, Parfitt A M, Manolagas S C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.  J Clin Invest. 1998;  102 274-282
    Google Scholar
  • 36 Weinstein R S, Manolagas S C. Apoptosis and osteoporosis.  Am J Med. 2000;  108 153-164
    Google Scholar
  • 37 Zelissen P M, Croughs R J, van Rijk P P, Raymakers J A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease.  Ann Intern Med. 1994;  120 207-210
    Google Scholar

Prof. Dr. M. Hüfner

Schwerpunkt Endokrinologie, Abteilung Gastroenterologie und Endokrinologie, Zentrum Innere Medizin, Georg-August-Universität

Robert Koch-Straße 40

37075 Göttingen

Phone: 0551/398902

Fax: 0551/392063

Email: mhuefner@med.uni-goettingen.de

      >